TITLE

Injection approved for macular degeneration

PUB. DATE
January 2005
SOURCE
Drug Topics;1/10/2005, Vol. 149 Issue 1, p8
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
Reports on the approval of Pegaptanib sodium injection 0.3 mg from Eyetech Pharmaceuticals/Pfizer, for the treatment of neovascular age-related macular degeneration.
ACCESSION #
15831851

 

Related Articles

  • New AMD treatment licensed. McCormick, Emily // Optometry Today;12/14/2012, Vol. 52 Issue 24, p6 

    The article reports that Bayer's Eylea injection treatment for wet age-related macular degeneration (AMD) has been approved for use in Europe and will be subjected for appraisal of the National Institute of Health and Clinical Excellence (NICE).

  • Eylea gets PBS green light.  // Australian Journal of Pharmacy;Dec2012, Vol. 93 Issue 1111, p42 

    The article reports that Eylea (aflibercept), a recombinant fusion protein for (wet) Age-related Macular Degeneration (wetAMD) was approved on the Pharmaceutical Benefits Scheme (PBS) listing on December 2012.

  • At OSI, a $935M poke in the Eye(tech). Harrell, Jeremy // Long Island Business News (7/1993 to 5/2009);11/10/2006, Vol. 53 Issue 51, p5A 

    The article reports developments surrounding the $935-million investment in cash and stock of OSI Pharmaceuticals Inc. to acquire the macular degeneration drug called Macugen from Eyetech Pharmaceuticals Inc. in Melville, New York in November 2005. At that time, analysts and stockholders...

  • Product Briefs.  // Biomedical Business & Technology;Feb2011, Vol. 34 Issue 2, p21 

    The article reports on U.S. Food and Drug Administration (FDA) clearance awarded to Advanced Cell Technology for its Investigational New Drug (IND) application for the treatment of dry age-related macular degeneration (AMD) via retinal pigment epithelial (RPE) cells derived from human embryonic...

  • Injection Shows Modest Success Against AMD.  // Review of Optometry;12/15/2003, Vol. 140 Issue 12, p6 

    Reports on the efficacy of pegaptanib sodium, an anti-VEGF drug injected into the eye, in blocking neovascularization in the wet form of age-related macular degeneration (AMD). Correlation of the presence of vascular endothelial growth factor (VEGF) in AMD with choroidal neovascularization;...

  • FDA Approves Eyetech/Pfizers Macugen.  // Review of Ophthalmology;Jan2005, Vol. 12 Issue 1, p4 

    The article reports that the U.S. food and Drug Administration has approved Macugen injection for the treatment of neovascular age-related macular degeneration. The injection has been developed by Eyetech Pharmaceuticals Inc. and Pfizer Inc. Macugen is the first in a new class of ophthalmic...

  • Research.  // Journal of Visual Impairment & Blindness;Jan2005, Vol. 99 Issue 1, p55 

    Reports on the approval received by Eyetech Pharmaceutical and Pfizer for the eye treatment Macugen. Benefits of Macugen for patients; Eye disease that can be treated by the drug.

  • Eyetech aims to be retina specialists' biotech resource. Dlugoss, Mark L. // Ophthalmology Times;6/1/2005, Vol. 30 Issue 11, p3 

    Reports on the projects being explored by New York-based Eyetech Pharmaceuticals to deliver medical solutions for the betterment of patients who suffer from blinding eye diseases. Implication of the U.S. Food and Drug Administration's approval of Eyetech's pegaptanib sodium injection product for...

  • Ranibizumab: higher dose linked to stroke.  // Reactions Weekly;2/10/2007, Issue 1138, p3 

    The article reports on a letter issued by Genentech advising of safety information regarding its ranibizumab injection. The letter was issued following interim data from the Safety Assessment of Intravitreal Lucentis for age-related macular degeneration (AMD) which showed that patients who...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics